Literature DB >> 21347717

Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.

Tian-Song Xia1, Jing-Ping Shi, Qiang Ding, Xiao-An Liu, Yi Zhao, Yue-Xian Liu, Jian-Guo Xia, Shui Wang, Yong-Bin Ding.   

Abstract

Spleen tyrosine kinase (Syk) is reported to be involved in the suppression of proliferation and invasion of breast cancer. Methylation-mediated Syk gene silencing is found in a subset of breast cancer. In this study, we used a DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (AZA), to restore Syk expression of breast cancer cells. Surprisingly, we found that AZA treatment could reestablish the expression of Syk, but not affect the proliferation of breast cancer cells. Moreover, tumor formation in situ by MDA-MB-435s treated with (+) or without (-) AZA in a nude mice MFP (Mammary fat pad) model did not show significant difference, too. Interestingly, pulmonary metastasis was still significantly suppressed in MDA-MB-435s(+) group (1/9 vs. 7/9). Our findings suggested Syk may be more correlated to metastasis rather than proliferation. This study implied a potential use of Syk methylation as a valuable biomarker to detect high metastatic potential cancerous lesions and the prospect of AZA to join the arsenal of drug candidates to be developed as a new reagent for management of advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21347717     DOI: 10.1007/s12032-011-9865-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.

Authors:  Ganapati H Mahabeleshwar; Gopal C Kundu
Journal:  J Biol Chem       Date:  2002-12-10       Impact factor: 5.157

2.  The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells.

Authors:  Christoph Hoeller; Christiane Thallinger; Barbara Pratscher; Malena D Bister; Nikolaus Schicher; Robert Loewe; Elisabeth Heere-Ress; Florian Roka; Veronika Sexl; Hubert Pehamberger
Journal:  J Invest Dermatol       Date:  2005-06       Impact factor: 8.551

3.  Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.

Authors:  Dirk L Kienle; Christian Korz; Beate Hosch; Axel Benner; Daniel Mertens; Annett Habermann; Alexander Kröber; Ulrich Jäger; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

4.  Hypermethylation leads to silencing of the SYK gene in human breast cancer.

Authors:  Y Yuan; R Mendez; A Sahin; J L Dai
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

5.  The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells.

Authors:  P J Coopman; M T Do; M Barth; E T Bowden; A J Hayes; E Basyuk; J K Blancato; P R Vezza; S W McLeskey; P H Mangeat; S C Mueller
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease.

Authors:  Teresa Marafioti; Michela Pozzobon; Martin-Leo Hansmann; Georges Delsol; Stefano A Pileri; David Y Mason
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

7.  Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer.

Authors:  Tatsuya Toyama; Hirotaka Iwase; Hiroko Yamashita; Yasuo Hara; Yoko Omoto; Hiroshi Sugiura; Zhenhuan Zhang; Yoshitaka Fujii
Journal:  Cancer Lett       Date:  2003-01-10       Impact factor: 8.679

8.  Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion.

Authors:  R M Larive; S Urbach; J Poncet; P Jouin; G Mascré; A Sahuquet; P H Mangeat; P J Coopman; N Bettache
Journal:  Oncogene       Date:  2009-05-04       Impact factor: 9.867

9.  Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells.

Authors:  Xiaoying Zhang; Ulka Shrikhande; Bethany M Alicie; Qing Zhou; Robert L Geahlen
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  5 in total

1.  Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.

Authors:  Mohit Sachdeva; Rebecca D Dodd; Zhiqing Huang; Carole Grenier; Yan Ma; Dina C Lev; Diana M Cardona; Susan K Murphy; David G Kirsch
Journal:  Cancer Lett       Date:  2015-08-24       Impact factor: 8.679

2.  Systems-Based Interactome Analysis for Hematopoiesis Effect of Angelicae sinensis Radix: Regulated Network of Cell Proliferation towards Hemopoiesis.

Authors:  Guang Zheng; He Zhang; Yun Yang; Ying-Li Sun; Yan-Jing Zhang; Ju-Ping Chen; Ting Hao; Cheng Lu; Hong-Tao Guo; Ge Zhang; Dan-Ping Fan; Xiao-Juan He; Ai-Ping Lu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

Review 3.  A Comparative Study on the In Vitro Effects of the DNA Methyltransferase Inhibitor 5-Azacytidine (5-AzaC) in Breast/Mammary Cancer of Different Mammalian Species.

Authors:  Rebecca M Harman; Theresa M Curtis; David J Argyle; Scott A Coonrod; Gerlinde R Van de Walle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2016-03-22       Impact factor: 2.673

4.  Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype.

Authors:  W A da Silveira; P V B Palma; R D Sicchieri; R A R Villacis; L R M Mandarano; T M G Oliveira; H M R Antonio; J M Andrade; V F Muglia; S R Rogatto; C Theillet; S du Manoir; D G Tiezzi
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

5.  Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells.

Authors:  Enrique Pérez-Cárdenas; Lucía Taja-Chayeb; Catalina Trejo-Becerril; José Chanona-Vilchis; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Elizabeth Langley; Alejandro García-Carrancá; Alfonso Dueñas-González
Journal:  Onco Targets Ther       Date:  2018-12-07       Impact factor: 4.345

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.